• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:AU2007346018A1
    申请号:U2007346018
    申请日:2007-10-10
    公开日:2008-08-07
    发明作者:Humberto Dos Santos Ferreira；Laszlo Erno Kiss；David Alexander Learmonth；Pedro Nuno Leal Palma；Patricio Manuel Vieira Araujo Soares Da Silva
    申请人:Bial Portela and Cia SA；
    IPC主号:A61K31-4439
    专利说明:
    WO 2008/094053 PCT/PT2007/000043 DOSAGE REGIMEN FOR COMT INHIBITORS This invention relates to novel substituted nitrocatechols and to their use in the treatment of central and peripheral nervous system disorders according to a specified dosing regimen. 5 The rationale for the use of COMT inhibitors as adjuncts to L-DOPA/AADC therapy is based on their ability to reduce metabolic O-methylation of L-DOPA to 3-0-methyl-L-DOPA (3-OMD). The duration of L-DOPA induced clinical improvement is brief as a result of the short in vivo half-life of L-DOPA which contrasts with the long half-life of 3-OMD. 10 Additionally, 3-OMD competes with L-DOPA for transport across the blood-brain barrier (BBB), which means that only a very limited amount of an orally administered dose of L-DOPA actually reaches the site of action, i.e. the brain. Commonly, within only a few years of starting L-DOPA therapy with the usual dosage regime, L-DOPA induced clinical improvement declines at the end of each dose cycle, giving rise to the so-called 'wearing-off 15 pattern of motor fluctuations. A close relationship between the 'wearing-off phenomenon and accumulation of 3-OMD has been described (Tohgi, H., et al., Neurosci. Letters,' 132:19-22, 1992). It has been speculated that this may result from impaired brain penetration of L-DOPA due to competition for the transport system across the BBB with 3-OMD (Reches, A. et al., Neurology, 32:887-888, 1982) or more simply that there is less L-DOPA available to reach 20 the brain (Nutt, J.G., Fellman, J.H., Clin. Neuropharmacol., 7:35-49, 1984). In effect, COMT inhibition protects L-DOPA from metabolic breakdown in the periphery through O-methylation, such that with repeated doses of L-DOPA, the mean plasma L-DOPA concentration is raised. In addition to reduced competition for transport into the brain, a significantly greater percentage of the orally administered dose of L-DOPA is able to reach 25 the site of action. Thus COMT inhibition serves to increase the bioavailability of L-DOPA and the duration of antiparkinsonian action is prolonged with single doses of L-DOPA (Nutt, J.G., Lancet, 351:1221-1222, 1998). The most potent COMT inhibitors thusfar reported are 3,4-dihydroxy-4'-methyl-5 30 nitrobenzophenone (Tolcapone, Australian pat. AU-B-69764/87) and (E)-2-cyano-NN diethyl-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide (Entacapone, German pat. DE 3740383 Al).
    WO 2008/094053 PCT/PT2007/000043 -2 Although sharing essentially the same pharmacophore, tolcapone differs from entacapone in that it easily enters the central nervous systems (CNS) and is able to inhibit cerebral COMT as well as peripheral COMT. However, shortly after its launch, tolcapone was withdrawn from the market after several cases of hepatotoxicity were reported including three unfortunate 5 deaths from fatal fulminant hepatitis. Today tolcapone can only be used in Parkinsonian patients who are unresponsive to other treatments and strictly only with regular monitoring of liver function, which is expensive and inconvenient for the patient. Although the actual mechanistic causes of the liver toxicity associated with tolcapone are not fully understood, in vitro studies have shown that tolcapone may be reduced metabolically to reactive 10 intermediates and it has been speculated that these may form covalent adducts with hepatic proteins resulting in hepatocellular injury (Smith, K.S. et al, Chem. Res. Toxicol., 16:123 128, 2003). Entacapone on the other hand, although sharing the same nitrocatechol pharmacophore with 15 tolcapone, is not associated with liver toxicity and is generally regarded as a safe drug. Unfortunately however, entacapone is a significantly less potent COMT inhibitor than tolcapone and has a much shorter in-vivo half-life. This means that entacapone has a very limited duration of effect and as a consequence, the drug must be administered in very high doses with every dose of L-DOPA taken by the patient. As such, the clinical efficacy of 20 entacapone has been questioned - indeed a recent study (Parashos, S.A. et al., Clin. Neuropharmacol., 27(3): 119-123, 2004) revealed that the principal reason for discontinuation of entacapone treatment in Parkinson's disease patients was a perceived lack of efficacy. Furthermore, the relatively short in-vivo half-life of known COMT inhibitors requires 25 continuous treatment regimens normally involving the administration of several doses a day which many patients find to be burdensome. For example, tolcapone has to be administered three times a day. This factor can therefore interfere with patient compliance and quality of life. 30 Accordingly, there is still a need for COMT inhibitors exhibiting balanced properties of bioactivity, bioavailability and safety. In particular, there is a need for COMT inhibitors WO 2008/094053 PCT/PT2007/000043 -3 having a long in-vivo half-life and, thus, a prolonged action on COMT enabling fewer dosages to obtain the desired therapeutic effect. We have now surprisingly found that compounds of general formula I are very potent COMT 5 inhibitors which are also endowed with exceptionally long duration of action compared to COMT inhibitors in the prior art. We have further surprisingly found that compounds of general formula I markedly enhance the bioavailability of L-DOPA and increase the delivery of L-DOPA to the brain. The 10 compounds significantly augment the levels of dopamine in the brain. Even more surprisingly, the increased levels of L-DOPA are maintained steady over a twenty four hour period. These effects upon both COMT activity and L-DOPA bioavailability at 24 h after the administration of compounds of general formula I are markedly greater than those 15 observed with tolcapone, the only COMT inhibitor thusfar known to be endowed with a reasonably long duration of action. At shorter time points (2 and 7 h) compounds of general formula I produce increases in L-DOPA delivery to the brain similar to those observed at 24 h, which contrasts to that observed with tolcapone. This results in a more steady delivery of L-DOPA to the brain after the administration of compounds of general formula I, whereas 20 tolcapone is prone to induce marked oscillations in the brain delivery of L-DOPA. Thus compounds of general formula I are more likely to be endowed with therapeutic advantages due to sustained constant elevation of L-DOPA levels whilst the use of tolcapone is likely to induce undesirable side-effects such as dyskinesia due to abrupt increases and decreases in L-DOPA levels. 25 WO 2008/094053 PCT/PT2007/000043 -4 Compounds of general formula I are compounds having the following formula
    NO
    2 RI0 R20 /O N (X)n (Y)m R3 (I) 5 where R 1 and R 2 are independently from each other hydrogen or a group which is hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl; X represents a methylene group; Y represents an atom of oxygen, nitrogen or sulphur; n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1; R 3 represents a pyridine N-oxide group according to the formula A, B or C, which is connected as indicated 10 by the unmarked bond: R7 R4 R7 R4 R7 +0 I I N, R6 N R5 R6 0 R6 R4 0 R5 R5 A B C 15 where R 4 , R 5 , R 6 and R 7 are the same or different, and signify hydrogen, lower alkyl, lower thioalkyl, lower alkoxy, aryloxy or thioaryl group, lower alkanoyl or aroyl group, optionally substituted aryl group, amino, lower alkylamino, lower dialkylamino cycloalkylamino or heterocycloalkylamino group, lower alkylsulphonyl or arylsulphonyl group, halogen 20 haloalkyl, trifluoromethyl, cyano, nitro or heteroaryl group, or taken together signify aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings; the term alkyl means carbon chains, straight or branched, containing from one to six carbon atoms; the term aryl means a WO 2008/094053 PCT/PT2007/000043 -5 phenyl or naphthyl group, optionally substituted by alkoxy or halogen groups; the term heterocycloalkyl represents a four to eight-membered cyclic ring optionally incorporating other atoms of oxygen, sulphur or nitrogen; the term heteroaryl represents a five or six membered ring incorporating an atom of sulphur, oxygen or nitrogen; the term halogen 5 represents fluorine, chlorine bromine or iodine. Preferably, in the above formula, R 4 , R 5 , R 6 and R 7 independently from each other represent hydrogen, C1-C 6 -alkyl, CI-C-thioalkyl,
    CI-C
    6 -alkoxy, C6-Cl 2 -aryloxy or a C6-C 12 -thioaryl group, C1-C6-alkanoyl or C7-Cn-aroyl group, amino, C 1
    -C
    6 - alkylamino, C1-C 6 -dialkylamino, 10 C3-C12-cycloalkylamino, C3-C1-heterocycloalkylamino, Cl-C6-alkylsulphonyl,
    C
    6
    -C
    1 2 arylsulphonyl, halogen, C1-C 6 -haloalkyl, trifluoromethyl, cyano, nitro or a heteroaryl group; or two or more of residues R 4 , R 5 , R 6 and R 7 taken together represent aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings. 15 Preferably, C1-C 6 -alkyl residues represent methyl, ethyl, n-propyl, isopropyl, n-butyl, sec butyl, tert-butyl, heptyl or hexyl. Preferably, C1-C 6 -thioalkyl residues represent thiomethyl, thioethyl, thio-n-propyl and thio-isopropyl and thio-n-butyl. Preferably, CI-C 6 -alkoxy residues represent methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy and tert butoxy. Preferably, C6-C1 2 -aryloxy residues represent phenoxy or naphthoxy which may 20 optionally be substituted. Preferably, C 6 -C 2-thioaryl residues represent thiophenyl and thionaphthyl which may optionally be substituted. Preferably, C-C 6 -alkanoyl residues represent methanoyl, ethanoyl, propanoyl or butanoyl. Preferably, C 7
    -C
    13 -aroyl residues represent benzoyl and naphthoyl. Preferably, C-C 6 - alkylamino residues represent methylamino, ethylamino, n-propylamino, isopropylamino and n-butylamino. Preferably, 25 C-C 6 -dialkylamino residues represent dimethylamino, diethylamino, di-n-propylamino, di-n butylamino, di-isopropylamino, methylethylamino, methylpropylamino and ethylpropylamino. Preferably, C3-C1-cycloalkylamino residues represent pyrrolidino, piperidino, cyclohexylamino and dicyclohexylamino. Preferably, C3-C1-heterocycloalkylamino residues represent morpholino, 2,6-dimethylmorpholino, 30 3,5-dimethylmorpholino, piperazino, N-methylpiperazino and N-ethylpiperazino. Preferably,
    C-C
    6 -alkylsulphonyl or C6-C 12 -arylsulphonyl residues represent methylsufonyl, ethylsulfonyl, phenylsulfonyl, and tolylsulfonyl. Preferably, halogen residues represent WO 2008/094053 PCT/PT2007/000043 -6 chloro, bromo, iodo and fluoro. Preferably, C-C 6 -haloalkyl represents chloromethyl, fluoromethyl, dichloromethyl, difluoromethyl, trichloromethyl and trifluoromethyl. Preferably, heteroaryl residues represent pyridyl, pyrimidyl, isoxazolyl, oxazolyl, isoxadiazolyl, oxadiazolyl, triazolyl and tetrazolyl. In cases where two or more of residues R 4 , 5 R 5 , R 6 and R 7 taken together represent aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings, preferred combined residues are indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, naphthyridinyl, isoquinolyl and quinolyl. Preferably, n and m each signify the number 0 or 1, or both signify 0 or 1. 10 In the following description of medical indications, treatments and dosing regimens for pharmaceutical compositions containing compounds according to general formula I of the invention, the most preferred example of a compound according to the general formula I is 5-[3-(2,5-dichloro-4,6-dimethyl-1 -oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene 1,2-diol, henceforth designated as compound A, and its pharmacologically acceptable salts 15 and esters. Other preferred compounds of the above general formula (I) in the subsequent medical indications, treatments and dosing regimens include 3-(5-(3,4-dihydroxy-5-nitrophenyl) 1,2,4-oxadiazol-3-yl)-4-(trifluoromethyl)pyridine- 1 -oxide, 2-chloro-3-(5-(3,4-dihydroxy-5 20 nitrophenyl)- 1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide, 3-(5-(3,4-dihydroxy-5 nitrophenyl)-1,2,4-oxadiazol-3-yl)-2-methyl-6-(trifluoromethyl)pyridine-1-oxide, 5-(5-(3,4 dihydroxy-5-nitrophenyl)- 1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)pyridine-1-oxide, 5-(5 (3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2-methyl-4-(trifluoromethyl)pyridine-1 oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,6-dimethyl-4 25 (trifluoromethyl)pyridine- 1-oxide, 3,5-dichloro-4-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4 oxadiazol-3-yl)pyridine- 1-oxide, 3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-6 methyl-2-phenyl-4-(trifluoromethyl)pyridine- 1-oxide, 2-bromo-3-(5-(3,4-dihydroxy-5 nitrophenyl)- 1,2,4-oxadiazol-3-yl)-4,5,6-trimethylpyridine- 1-oxide, 2-chloro-3-(5-(3,4 dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,5,6-trimethylpyridine-1-oxide, 3-(5-(3,4 30 dihydroxy-5-nitrophenyl)- 1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)pyridine-1 -oxide, 2 chloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-6-methylpyridine 1-oxide, 2 bromo-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-6-methylpyridine-1-oxide, WO 2008/094053 PCT/PT2007/000043 -7 2 -bromo-5-chloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6 dimethylpyridine- 1-oxide 5-[3-(2-chloro- 1 -oxy-pyridin-4-yl)-[ 1,2,4]oxadiazol-5-yl] -3-nitro benzene- 1,2-diol, 5-[3-(2-morpholin-4-yl-1-oxy-pyridine-4-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro benzene-1,2-diol, 5-[3-(4-bromo-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzene 5 1,2-diol, 5-[3-(2-morpholin-4-yl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitro-benzene 1,2-diol, 5-[3-(2-methyl-1-oxy-6-phenyl-4-trifluoromethyl-pyridin-3-yl)-[l,2,4]oxadiazol-5 yl]-3-nitro-benzene-1,2-diol and 5-[3-(2-bromo-4,6-dimethyl-1-oxy-pyridin-3-yl) [1,2,4]oxadiazol-5-yl]-3-nitro-benzene-1,2-diol and their pharmacologically acceptable salts and esters. 10 The present invention relates to the use of the compounds of general formula I, their pharmaceutically acceptable salts or esters for the prevention or treatment of certain pathological states, especially in humans, (e.g. central and peripheral nervous system disorders) and to preparation of pharmaceutical compositions containing them. 15 Preferably, the treated pathological states are central and peripheral nervous system associated disorders of humans. Preferred disorders include movement disorders and schizoaffective disorders. Movement disorders are characterised by either a lack of movement or excessive movement. Movement disorders preferably treated by compounds of general formula I 20 include Parkinson disease,dystonia, dyskinesia, extrapyrimidal syndromes, gait, tremor, chorea, ballism, akathisia, athetosis, bradykinesia, freezing, rigidity, postural instability, myoclonus, and tics or Tourette syndrome. The most preferred disorder is Parkinson's Disease. 25 As used herein, the term treatment and variations such as 'treat' or 'treating' refer to any regime that can benefit a human or non-human animal. The treatment may be in respect of an existing condition or may be prophylactic (preventative treatment). Treatment may include curative, alleviation or prophylactic effects. Treatment may prevent or delay the onset, retard the progression or ameliorate the symptoms of the disease or condition. 30 WO 2008/094053 PCT/PT2007/000043 -8 The compounds of the general formula I are preferably used for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders according to a specified dosing regimen. 5 Suitable dosing regimens comprise regimens having a dosing periodicity ranging from about twice a day to about once every other day. As used herein, the term dosing periodicity refers to the number of effective doses of a compound of general formula I given in the specified time interval. 10 Preferably, the dosing periodicity is selected from twice per day, once per day and once every other day. In case of a dosage periodicity of twice daily, the effects of the invention may be achieved by 15 administration once in each 12 hour period even where the time between administrations (or dosing interval) is not 12 hours. The doses are preferably administered in dosing intervals of 8 to 16 hours, more preferably 12 hours, wherein two dosing intervals preferably accumulate to about 24 hours. Suitable non-limiting starting points for dosing intervals comprise the morning, mid-day, noon, afternoon, evening, and midnight. For example, a twice daily dosing 20 regimen according to the invention can require the administration of a dose at 8.00 in the morning and another dose at 17.00 in the afternoon (in this case, the dosing intervals are 11 hours and 13 hours and add up to about 24 hours). Preferably, the time interval between two doses is about 12 h. 25 In case of a dosage periodicity of once daily, the effects of the invention may be achieved by administration once in each 24 hour period even when the time between administrations is not 24 hours. The doses are preferably administered in dosing intervals of about 24 hours. Suitable non-limiting starting points for dosing intervals comprise the morning, mid-day, noon, afternoon, evening, and midnight. For example, a once daily dosing regimen according 30 to the invention can require the administration of a dose at 8.00 in the morning and another dose at 8.00 on the morning of the following day (in this case, the dosing interval is about 24 h).
    WO 2008/094053 PCT/PT2007/000043 -9 In case of a dosage periodicity of once every other day, the effects of the invention can be achieved by administration once in each 48 hour period even where the time between administrations is not 48 hours. The doses are preferably administered in dosing intervals of 5 36 to 60 hours, wherein the dosing intervals preferably average about 48 hours. Suitable non limiting starting points for dosing intervals comprise the morning, mid-day, noon, afternoon, evening, and midnight. For example, a once every other day dosing regimen according to the invention can require the administration of a dose at 8.00 in the morning on the first day and another dose at 13.00 in the afternoon of the third day (in this case, the dosing interval is 10 53 hours). Preferably, the time between each administration is about 48 h. In the present invention, effective daily doses of compounds of general formula I are in the range of 1-1000 mg/day, more preferably 2 to 500 mg/day, even more preferably 3 to 250 mg/day, and most preferably 5-100 mg/day. 15 It is preferred that individual dosage units of compounds of general formula I are in the range of 1-500 mg, more preferably 2 to 300 mg/day, even more preferably 3 to 100 mg/day, and most preferably 5-50 mg, wherein the daily dosage can differ depending on the time of administration. For instance, in a twice daily dosing regimen, it is possible to administer a 20 dose containing 11/24 of the daily dose of a compound of general formula I at 8.00 in the morning and another dose containing 13/24 of the daily dose of a compound of general formula I at 17.00 in the afternoon. As used herein, the term "dosage unit" refers to the individual pharmaceutical formulation, 25 e.g. a tablet, containing the compound of general formula I to be administered to a patient at that time of the dosage regimen. Preferably the subject being treated with the compound of general formula I is also receiving therapy with L-DOPA and/or an aromatic L-amino acid decarboxylase inhibitor (AADC). 30 Suitable AADC include carbidopa and benserazide.
    WO 2008/094053 PCT/PT2007/000043 -10 The compounds of general formula I, L-DOPA and AADC may be administered separately or in any combination. They may be administered concomitantly (for example, simultaneously) or sequentially and with the same or differing dosing periodicity. For example, the compounds of the general formula I can be concomitantly or sequentially administered with 5 L-DOPA. In case of concomitant administration it is also possible to combine both active ingredients in one pharmaceutical formulation. According to another aspect of the present invention there is provided a method of treating at least one condition or disease in a patient in need thereof comprising administering about 10 twice per day to about once every other day a pharmacologically effective dose of a compound of general formula I as defined above to the patient. Preferably the administration is once per day for all embodiments of the invention. 15 Preferably in all methods of the invention the subject being treated with the compound of general formula I is also receiving therapy with L-DOPA and/or an aromatic L-amino acid decarboxylase inhibitor (AADC). According to another aspect of the invention there is provided a method for reducing COMT 20 inhibition in a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject. According to another aspect of the invention there is provided a method for increasing levels 25 of L-DOPA in the brain of a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject. According to another aspect of the invention there is provided a method for increasing levels 30 of L-DOPA in the plasma of a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject.
    WO 2008/094053 PCT/PT2007/000043 - 11 According to another aspect of the invention there is provided a method for decreasing levels of 3-0-methyl-L-DOPA (3-OMD) in the brain of a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject. 5 According to another aspect of the invention there is provided a method for decreasing levels of 3-OMD in the plasma of a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject. 10 According to another aspect of the invention there is provided a method for increasing bioavailability of L-DOPA in the brain of a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject. 15 According to another aspect of the invention there is provided a method for increasing bioavailability of L-DOPA in the plasma of a subject over 24 to 48 hours, comprising administering, about twice per day to about once every other day, an effective dose of a compound of general formula I as defined above to the subject. 20 According to a further aspect of the invention, there is provided a pharmaceutical composition adapted for the administration of a compound of general formula I from about twice per day to about once every other day. 25 The present invention also relates to a package comprising a pharmaceutical composition of a compound of the general formula I in combination with instructions to administer said formulation with a dosing regimen having a dosing periodicity ranging from twice per day to about once every other day. 30 In one embodiment, the compounds of the general formula I can be prepared by a process wherein a compound of the general formula IIA, JIB or IIC, WO 2008/094053 PCT/PT2007/000043 -12 HON
    NH
    2 R 7 NOH R6
    R
    7 R4 R6 NH2 R5 R7
    R
    6 N R 5
    R
    5 N R 4
    R
    4 N NOH 0 0 0 IIA IIB IC wherein R 4 , R 5 , R 6 and R 7 are as defined in the general formula I, is subjected to a cyclisation 5 reaction comprising condensation and dehydration with a compound of the general formula III,
    R
    8 0 CO 2 H
    R
    9 0
    NO
    2 10 (III), wherein R 8 and R 9 independently from each other represent hydrogen or suitable protective groups for aromatic hydroxyl groups, under conditions suitable to produce oxadiazole derivatives of formula IVA, IVB or IVC, 15
    NO
    2
    NO
    2
    NO
    2 R 9 0 R 9 0 "! R 9 0 '
    R
    8 0 I N R 8 0 R 8 0 I N NO N N 0 N' R7 R5 RN N- 0 R 7 R
    R
    6 R 6
    R
    5
    R
    6
    R
    5 IVA IVB IVC Followed, if required, by removal of the hydroxyl protecting groups to provide the 20 compounds of general formula I.
    WO 2008/094053 PCT/PT2007/000043 - 13 In another embodiment, the compounds of the general formula I can be prepared by a process wherein a compound of the general formula VA, VB or VC, HON
    NH
    2 R 7 NOH R6
    R
    7
    R
    4 R6 NH 2 R6 R 7
    NH
    2
    R
    6 N R 5
    R
    5 N R 4
    R
    4 N NOH 5 VA VB VC wherein R 4 , R 5 , R 6 and R 7 are as defined in the general formula I, is subjected to a cyclisation reaction comprising condensation and dehydration with a compound of the general formula III under conditions suitable to produce oxadiazole derivatives of formula VIA, VIB or VIC, 10
    NO
    2
    NO
    2
    NO
    2
    R
    9 0 R 9 0 R 9 0
    R
    8 R80 8 0 INR 8 0 0 N N0 N SR7 N R7N R7 -NR5 -RR R6
    R
    6
    R
    5 R 6 R5 VIA VIB VIC followed by oxidation of the pyridyl nitrogen atom to give a compound according to formula 15 IVA, IVB or IVC as shown above and, if required, the removal of the hydroxyl protecting groups to provide the compounds of general formula I. Suitable protective groups for aromatic hydroxyl groups are well known in the art. Examples of suitable protective groups for aromatic hydroxyl groups include methyl, ethyl, isopropyl, 20 benzyl, 4-methoxybenzyl, methoxymethyl, benzyloxymethyl, methoxyethoxymethyl, tetrahydropyranyl, phenacyl, allyl, trimethylsilyl, tert-butyldimethylsilyl, benzyloxycarbonyl, tert-butoxycarbonyl, ester, sulphonate, carbamate, phosphinate, acetal and ketal derivatives.
    WO 2008/094053 PCT/PT2007/000043 - 14 In a preferred embodiment, one of the groups R 8 and R 9 is hydrogen and the other is methyl. In a particularly preferred embodiment, R 8 represents methyl and R 9 represents hydrogen. In an alternative preferred embodiment, the protective groups R 8 and R 9 are replaced with 5 hydrogen or a group which is hydrolysable under physiological conditions. The protective groups R 8 and R 9 may be removed independently from each other in separate reaction steps or they may be removed in the same reaction step. Likewise, the insertion of a group which is hydrolysable under physiological conditions may take place either in the same or in a subsequent reaction step. 10 In the present invention, conditions suitable to produce oxadiazole derivatives comprise conditions which give the oxadiazole derivative in high yield and purity. Preferably, the yield of the desired oxadiazole derivative is at least 70 %, more preferably 75 to 99 %, even more preferably 80 to 97 %, and most preferably 85 to 95 %. Preferably, the purity of the desired 15 oxadiazole derivative is at least 90 %, more preferably at least 95 %, even more preferably at least 99 %, and most preferably at least 99.5 %. Following the teaching of the present invention the skilled person can routinely determine the most suitable reaction conditions in order to optimize the yield and purity of the oxadiazole. Parameters to be taken into consideration by the skilled person include, but are not limited to, reagents effecting the 20 condensation and dehydration agents, choice of protective groups R 8 and R 9 , solvent system, reaction temperature and reaction time and solubility of reagents. The compound of general formula III requires activation before the condensation reaction with a compound of formula IIA-IIC or VA-VC. Suitable reagents for activation of the 25 compound of formula III include 1,1-carbonyldiimidazole, thionyl chloride, sulfonylchloride, N,N'-dicyclohexylcarbodiimide, 1 -hydroxybenzotriazole and N-(3-dimethylaminopropyl)-N' ethylcarbodiimide, phosgene, PCl 3 , POCl 3 , PC 5 , anhydrides, trichlorotriazine and chlorodimethoxytriazine and the like. Particularly preferable are 1,1-carbonyldiimidazole and thionyl chloride. In some cases, the same reagents can be employed to effect the cyclisation 30 step, which consists of condensation and dehydration. Alternative reagents to effect condensation and and/or dehydration include pyridine and tetrabutylammonium fluoride.
    WO 2008/094053 PCT/PT2007/000043 - 15 Preferably the dehydration can be effected by thermal heating of the reaction mixture in conjunction with the aforementioned reagents. The compound of general formula III can be activated with an excess of a reagent such as 5 thionyl chloride in a suitable solvent or without the need for additional solvent. If preferred, the excess reagent can then be removed, e.g. by distillation, and replaced with a solvent and another reagent such as pyridine to effect the condensation and dehydration steps. Preferred solvent systems for activating the compound of general formula III, and cyclisation with compounds of general formulae IIA-IIC or VA-VC are dipolar aprotic solvents including 10 dimethylformamide, dimethylsulfoxide, dimethylacetamide and N-methylpyrrolidinone. Particularly preferable are dimethylsulfoxide and dimethylacetamide. Suitable reaction temperatures and reaction times depend on the reactivity of the utilized reagents for effecting condensation and dehydration. Preferably, the reaction temperature is in 15 the range of 0 0 C to the boiling point of the utilized solvent system, more preferably in the range of 20 to 150'C, and most preferably in the range of 25 to 120 *C. Preferably, the reaction time is in the range of 30 minutes to 24 hours, more preferably in the range of 1 hour to 18 hours, and most preferably 2 to 6 hours. 20 In an alternative preferred embodiment, the condensation and dehydration reaction is carried out in the presence of an organic or inorganic base. Suitable preferred bases include triethylamine, tributylamine, 2,6-lutidine, N-methylmorpholine, pyridine, imidazole, N-methylimidazole and 4-dimethylaminopyridine. Particularly preferred bases include pyridine, N-methylimidazole and 4-dimethylaminopyridine. 25 In a preferred embodiment of the present invention, the condensation and dehydration are conducted in two separate reaction steps. In this particular embodiment, different condensation and dehydration agents and solvent systems may be utilized to optimize yield and purity of the obtained product. 30 In an alternative preferred embodiment of the present invention, the condensation and dehydration are conducted sequentially in the same vessel without isolation of the O-acylated WO 2008/094053 PCT/PT2007/000043 - 16 intermediates. In this particular embodiment, the reagents effecting the condensation and dehydration can be the same or different but are preferably identical. The amount of reagents effecting the condensation and dehydration are not critical. Typical 5 amounts of reagents effecting the condensation and dehydration include at least an amount of 1 mol, preferably 2.1 mol to 5 mol, more preferably 2.2 to 4 mol, and most preferably 2.3 mol to 3 mol, per mol pyridine derivative. In cases in which the reagents effecting the condensation and dehydration also serve as solvent or co-solvent, the excess amount may be much higher. 10 As mentioned above, in preferred embodiments the invention includes a step in which the nitrogen atom of the pyridyl moiety VIA, VIB or VIC is oxidized under suitable conditions to the corresponding pyridyl-N-oxide derivative IVA, IVB or IVC after the cyclisation reaction. 15 In the present invention, suitable oxidative conditions to produce the pyridyl-N-oxide comprise conditions which give the pyridyl-N-oxide derivative in high yield and purity. Preferably, the yield of the desired pyridyl-N-oxide derivative is at least 90 %, more preferably 92 to 99 %, even more preferably 94 to 98 %, and most preferably 95 to 97 %. Preferably, the purity of the desired pyridyl-N-oxide derivative is at least 90 %, more 20 preferably at least 95 %, even more preferably at least 99 %, and most preferably at least 99.5 %. Following the teaching of the present invention the skilled person can routinely determine the most suitable reaction conditions in order to optimize the yield and purity of the pyridyl N-oxide. Parameters to be taken into consideration by the skilled person include, but are not limited to, oxidizing agent, amount of oxidizing agent, choice of protective groups, solvent 25 system, reaction temperature and reaction time and solubility of reagents. Preferred oxidizing agents include hydrogen peroxide, MnO 2 , peracetic acid, trifluoroperacetic acid, t-butylhydroperoxide, m-chloroperoxybenzoic acid, persulfuric acids, Oxone@, urea-hydrogen peroxide complex and trifluoroacetic anhydride, pyridinium 30 chlorochromate and permanganate ions. Particularly preferred is urea-hydrogen peroxide complex and trifluoroacetic anhydride.
    WO 2008/094053 PCT/PT2007/000043 -17 The preferred amount of oxidizing agent is in the range of equimolar amounts to a 20-fold excess to the pyridine derivative. Preferably, amount of oxidizing agent is in the range of a 1.2-fold to 10-fold excess, more preferably 1.5-fold to 8-fold excess and most preferably 2 fold to 5-fold excess. 5 Preferred solvent systems for conducting the oxidation are solvents which are inert to the oxidizing agent. Particularly preferred are halogenated solvents, such as dichloromethane, chloroform, chlorobenzene and carbon tetrachloride, aromatic solvents such as benzene and toluene, alkanes such as cyclohexane and hexane, and ethers such as THF, 1,4-dioxane and 10 tert-butylmethylether. Suitable reaction temperatures and reaction times depend on the reactivity of the utilized oxidizing agent. Preferably, the reaction temperature is in the range of 0 0 C to the boiling point of the utilized solvent system, more preferably in the range of 20 to 100'C, and most 15 preferably in the range of 40 to 80 *C. Preferably, the reaction time is in the range of 30 minutes to 24 hours, more preferably in the range of 1 hour to 18 hours, and most preferably 2 to 6 hours. The oxidation of the pyridyl nitrogen atom can be carried out at any stage of the process of 20 preparation of compounds according to the general formula I. Preferably, the oxidation is conducted before formation of the compounds of formulae IIA-IIC, or alternatively after formation of the oxadiazole ring as in compounds of formulae VIA-VIC. In another aspect of the invention, compounds of formula IIA, IIB or IIC are prepared by 25 reacting compounds of the general formula VIIA, VIIB or VIIC, CN Ry R6 Ry R4 R 6 CN R 5 R7
    R
    6 N R 5
    R
    5 N R 4
    R
    4 N CN 0 0 0 VIIA VJJB VIJC WO 2008/094053 PCT/PT2007/000043 - 18 with hydroxylamine in the presence of a chelating agent under suitable reaction conditions. In another aspect of the invention, compounds of formula VA, VB or VC are prepared by reacting compounds of the general formula VIIIA, VIIIB or VIIIC, 5 CN R7 R 6
    R
    7 ; , R 4
    R
    6 CN R 5
    )R
    7
    R
    6 N R 5
    R
    5 N R 4
    R
    4 N CN VIIIA VIIIB VIIIC with hydroxylamine in the presence of a chelating agent under suitable reaction conditions. 10 In the present invention, suitable reaction conditions of the above reactions comprise conditions which give the amidoxime derivative in high yield and purity. Preferably, the yield of the desired amidoxime derivative is at least 70 %, more preferably 72 to 95 %, even more preferably 75 to 90%, and most preferably 78 to 85%. Preferably, the purity of the 15 desired amidoxime derivative is at least 90 %, more preferably at least 95 %, even more preferably at least 96 %, and most preferably at least 97 %. Following the teaching of the present invention the skilled person can routinely determine the most suitable reaction conditions in order to optimize the yield and purity of the amidoxime. Parameters to be taken into consideration by the skilled person include, but are not limited to, amount of 20 hydroxylamine, choice of catalyst, nature of substituents R 4
    -R
    7 , solvent system, reaction temperature and reaction time and solubility of reagents. The preferred amount of hydroxylamine is in the range of equimolar amounts to a 50-fold excess to the pyridine derivative. Preferably, the amount of hydroxylamine is in the range of a 25 1.2- fold to 20-fold excess, more preferably 1.5-fold to 10-fold excess and most preferably 3-fold to 5-fold excess. Preferred chelating agents include 8-hydroxyquinoline, ortho-phenanthroline and hydrates and derivatives thereof. The preferred amount of chelating agent is in the range 0.1-10 mol %, WO 2008/094053 PCT/PT2007/000043 -19 more preferably 0.5-5 mol %, more preferably 0.75-3 mol % and most preferably 1-1.5 mol The solvent system is not particularly limited and includes water, alcohols such as methanol, 5 ethanol or isopropanol, ethers such as THF or 1,4-dioxane, and dipolar aprotic solvents, such as dimethylsulfoxide and the like or mixtures of these solvents. Preferably, the reaction temperature is in the range of 0*C to the boiling point of the utilized solvent system, more preferably in the range of 20 to 100*C, and most preferably in the range 10 of 40 to 80 'C. Preferably, the reaction time is in the range of 30 minutes to 24 hours, more preferably in the range of 1 hour to 18 hours, and most preferably 2 to 8 hours. The bioavailability, bioactivity, safety profile and other related properties known in the art (e.g. blood-brain-barrier permeability) of the compounds of general formula I can be routinely 15 optimized by the skilled person on basis of the teaching of the present application by varying substituents R 1
    -R
    7 of the above general formula I in order to obtain a desirable balanced mix of properties. The compounds of general formula I may also be present in the form of pharmacologically 20 acceptable salts thereof. Suitable pharmaceutically acceptable counter ions are known to the art. It is also possible to use prodrugs of compounds of the general formula I in order to alter the therapeutic profile of the active compound. 25 Materials and Methods Assay of COMT activity 30 Livers from 60 day old male Wistar rats weighing 240-260 g (Harlan-Interfauna Ibdrica, Barcelona, Spain), kept two per cage under controlled environmental conditions (12 h WO 2008/094053 PCT/PT2007/000043 - 20 light/dark cycle and room temperature 24 'C) were used in all experiments. After decapitation, the organs were immediately removed and homogenised in 5 mM phosphate buffer of pH 7.8. COMT activity was evaluated by the ability to methylate adrenaline to metanephrine. Aliquots of 0.5 ml of liver homogenates were preincubated for 20 min with 5 0.4 ml of phosphate buffer (5 mM); thereafter, the reaction mixture was incubated for 15 min with epinephrine (2000 pM; 0.1 ml) in the presence of a saturating concentration of S adenosyl-L-methionine (500 pM), the methyl donor; the incubation medium contained also pargyline (100 M), MgCl 2 (100 pM) and EGTA (1 mM). The preincubation and incubation were carried out at 37'C under conditions of light protection with continuous shaking and 10 without oxygenation. In experiments designed to evaluate the oral bioavailability of test substances, compounds were given by gastric tube to overnight fasted rats. Thereafter, at defined intervals, animals were killed by decapitation and livers removed and used to determine COMT activity as 15 described above. At the end of the incubation period (5 min) the tubes were transferred to ice and the reaction was stopped by the addition of 200 pl of 2 M perchloric acid. The samples were then centrifuged (200xg, 4 min, 4"C), and 500 p1 aliquots of the supernatant, filtered on 0.22 pm pore size Spin-X filter tubes (Costar) were used for the assay of metanephrine. The assay of metanephrine was carried out by means of high pressure liquid chromatography with 20 electrochemical detection. The lower limits for detection of metanephrine ranged from 350 to 500 finol (0.5 to 1.0 pmol/mg protein/h). Levels of L-DOPA and its derivatives in whole brain and plasma 25 Rats fasted overnight were administered orally with tolcapone and compounds of general formula I (3 mg/kg) or vehicle (0.5% carboxymethylcellulose, 4 ml/kg). One, 6 or 23 h later, rats were administered orally with L-DOPA (12 mg/kg) plus benserazide (3 mg/kg) or with vehicle (0.5% carboxymethylcellulose, 4 ml/kg). One hour later rats were anaesthetised with 30 sodium pentobarbitone (60 mg/kg, i.p.), blood was collected through the vena cava and the whole brain was quickly removed. Brains were stored in perchloric acid 0.2 M for subsequent assay of L-DOPA, 3-0-methyl-L-DOPA, dopamine, DOPAC and HVA. Blood samples were WO 2008/094053 PCT/PT2007/000043 -21 centrifuged for 15 min at 3,000 g (4"C) and the plasma samples were stored at -80"C till the assay of L-DOPA and 3-0-methyl-L-DOPA. All animals interventions were performed in accordance with the European Directive number 86/609, and the rules of the "Guide for the Care and Use of Laboratory Animals", 7th edition, 1996, Institute for Laboratory Animal 5 Research (ILAR), Washington, DC. Assay of L-DOPA and catechol derivatives 10 L-DOPA, 3-O-methyl-L-DoPA, dopamine and metabolites (DOPAC and HVA) in dialysate samples were assayed by HPLC with electrochemical detection, as previously described (Soares-da-Silva et al., Brain Res. 2000;863:293-297). In brief, aliquots of 20 R1 were injected into the chromatograph. The chromatographic system consisted of a pump (Gilson 307) and a stainless steel 5 [tm ODS2 column (Biophase; Bioanalytical Systems, West Lafayette, IN) of 15 25 cm length and 4.6 mm diameter; samples were injected by means of an automatic sample injector (Gilson 231) connected to a Gilson dilutor (Gilson 401). The mobile phase was a degassed solution of citric acid 0.1 mM; sodium octylsulphate 0.5 mM; sodium acetate 0.1 M; Na 2 EDTA 0.17 mM; dibutylamine 1 mM and methanol (10% v/v), adjusted to pH 3.5 with PCA 2 M and pumped at a rate of 1.0 ml min~'. The detection was carried out 20 electrochemically with a glassy carbon electrode, an Ag/AgC1 reference electrode and an amperometric detector (Gilson 142); the detector cell was operated at 0.75 V. The current produced was monitored using the Gilson Unipoint HPLC software. The lower limit of detection of dopamine, DOPAC and HVA ranged from 350 to 1000 fmol.
    WO 2008/094053 PCT/PT2007/000043 - 22 Description of the Figures Figure 1. Effect of compound A and tolcapone (3 mg/kg) on liver COMT activity at 0.5, 1, 3, 6, 9, 24 and 48 h after the administration of the COMT inhibitor. Symbols represent means I 5 SEM of 5 experiments per group. Significantly different from corresponding controls values (* P<0.05). Figure 2. Effect of compound A and tolcapone (3 mg/kg) on plasma levels of L-DOPA and 3-0-methyl-L-DOPA in rats treated with L-DOPA (12 mg/kg) plus benserazide (3 mg/kg), at 10 2, 7 and 24 h after the administration of the COMT inhibitor. Columns represent means + SEM of 5 experiments per group. Significantly different from corresponding controls values (* P<0.05). Figure 3. Effect of compound A and tolcapone (3 mg/kg) on brain levels of L-DOPA, 3-0 15 methyl-L-DOPA, dopamine, DOPAC and HVA in rats treated with L-DOPA (12 mg/kg) plus benserazide (3 mg/kg), at 2, 7 and 24 h after the administration of the COMT inhibitor. Columns represent means + SEM of 5 experiments per group. Significantly different from corresponding controls values (* P<0.05). 20 Results Compounds of general formula I, e.g. compound A, were found to be potent inhibitors of liver COMT, the maximal inhibitory effect being achieved within 60 min after their oral 25 administration (Figure 1). The maximal inhibitory effect of tolcapone was observed within 30 min after administration (Figure 1). Nine hours after administration, tolcapone produces minimal inhibitory effects, whereas compounds of general formula I, e.g. compound A, continues to inhibit COMT activity at 90% of control levels (Figure 1). As shown in Figure 1, even at 24 hours after administration, compounds of general formula I, e.g. compound A, 30 are capable of inhibiting liver COMT at 60% of controls levels, whereas tolcapone was again almost devoid of COMT inhibitory properties.
    WO 2008/094053 PCT/PT2007/000043 - 23 Figure 2 shows levels of L-DOPA and 3-0-methyl-L-DOPA in plasma of rats treated with L-DOPA plus benserazide at 2, 7 and 24 h after the administration of tolcapone and compounds of general formula I, e.g. compound A, (3 mg/kg). L-DOPA plus benserazide were administered 1 h before collection of blood samples. This time-point was chosen 5 because it represented the Tmax for L-DOPA. As can be observed, compounds of general formula I, e.g. compound A, produced significant increases in plasma L-DOPA accompanied by marked decrease in circulating 3-0-methyl-L-DOPA, this being identical at all pre treatment times with compounds of general formula I, e.g. compound A, (1, 7 and 24 h). Plasma levels of L-DOPA and 3-0-methyl-L-DOPA are not affected when tolcapone was 10 administered 24 h in advance. Significant changes on L-DOPA and 3-0-methyl-L-DOPA plasma levels by tolcapone were only observed at shorter time points 2 and 7 h after the administration of the compound. Figure 3 shows levels of L-DOPA, 3-0-methyl-L-DOPA, DOPAC, dopamine and HVA in 15 the brain of rats treated with L-DOPA plus benserazide at 2, 7 and 24 h after the administration of tolcapone and compounds of general formula I, e.g. compound A, (3 mg/kg). L-DOPA plus benserazide were administered 1 h before collection of brain samples. This time-point was chosen because it represented the Tmax for L-DOPA. As can be observed, compounds of general formula I, e.g. compound A, produced significant increases in brain 20 L-DOPA, dopamine and DOPAC accompanied by marked decrease in brain 3-0-methyl L-DOPA, this being identical at all pre-treatment times with compounds of general formula I, e.g. compound A, (1, 7 and 24 h). Brain levels of L-DOPA, dopamine, DOPAC and 3-0 methyl-L-DOPA were not affected when tolcapone was administered 24 h in advance. Significant changes to L-DOPA, dopamine, DOPAC and 3-0-methyl-L-DOPA brain levels 25 by tolcapone were only observed at 2 and 7 h after the administration of the compound. The invention will now be described with reference to the following example of preparation, which is not intended to limit the invention in any way.
    WO 2008/094053 PCT/PT2007/000043 -24 Example 1 - Preparation of compound A (5-[3-(2,5-Dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene 1,2-diol) 5 a) To a stirred solution of 3,4-dibenzyloxy-5-nitrobenzoic acid (0.50 g, 1.318 mmol) in dimethylformamide (5 mL) at room temperature was added 1,1-carbonyldiimidazole (0.24 g, 1.48 mmol) in one portion. After stirring for ninety minutes, 2,5-dichloro-N'-hydroxy-4,6 dimethylnicotinimidamide (0.40 g, 1.71 mmol) was added in one portion. The resulting 10 mixture was stirred at 135 'C for five hours and then at room temperature overnight. The reaction mixture was poured onto ice-2 N HCJ (100 mL) and the resulting precipitate was filtered off, washed with water and dried in air. Recrystallisation from isopropanol gave a pale yellow solid (0.55 g, 72 %). 15 b) To a stirred solution of the solid obtained above (0.50 g, 0.866 mmol) in dichloromethane (20 mL) was added urea-hydrogen peroxide addition complex (0.41 g, 4.36 mmol) in one portion. The mixture was cooled in an ice-water batch and trifluoroacetic anhydride (0.73 g, 3.48 mmol) was added dropwise. The, reaction mixture was allowed to stir at room temperature overnight whereupon insoluble material was filtered off. The filtrate was washed 20 with water and brine, dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was crystallised from isopropanol to give a pale yellow solid (0.35 g, 68 %). c) To a stirred solution of the solid obtained above (0.30 g, 0.5 mmol) in dichloromethane (10 mL) at -78 *C under argon was added boron tribromide (0.38 g, 1.5 mmol) dropwise. The 25 resulting purple suspension was allowed to stir at room temperature for one hour, then cooled again to -78 *C and carefully quenched by the addition of water. After stirring at room temperature for one hour, the precipitate was filtered off, washed with water and dried at 50 *C under vacuum to afford the desired compound as yellow crystals (0.18 g, 86 %) of m.p. 237-240 0 C. 30 WO 2008/094053 PCT/PT2007/000043 - 25 Example 2 - Pharmaceutical formulation Suitable exemplary pharmaceutical formulations are prepared according to the following specifications: 5 Capsule: Compound A 15.0% Lactose monohydrate 43.0% Microcrystalline cellulose 30.0% 10 Povidone 4.0% Croscarmellose sodium 5.0% Talc 2.0% Magnesium stearate 1.0% 15 Capsule: Compound A 15.0% Microcrystalline cellulose 72.5% Ethylcellulose 5.0% Sodium starch glycolate 6.0% 20 Colloidal Silicon Dioxide 0.5% Magnesium stearate 1.0% Tablet: Compound A 20.0% 25 Microcrystalline cellulose 25.0% Calcium Phosphate, dibasic dihydrate 40.0% Povidone 6.0% Croscarmellose sodium 6.0% Talc 2.0% 30 Magnesium stearate 1.0% WO 2008/094053 PCT/PT2007/000043 - 26 Example 3 - Dosing regimen Patients suffering from a movement disorder and who are on L-DOPA therapy are treated with tablets containing 50 mg of compound of the general formula I . A significant 5 improvement in the clinical picture is evidenced.
    权利要求:
    Claims (29)
    [1] 1. Use of a compound of formula I NO 2 Ri0 0 R200 RO I N (X)n Y)m 5 R3 5 where R 1 and R2 are the same or different and signify hydrogens or groups hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl; X signifies 10 a methylene group; Y represents an atom of oxygen, nitrogen or sulphur; n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1; R 3 signifies a pyridine N-oxide group according to the formula A, B, or C, which is connected as indicated by the unmarked bond: R7 R4 R7 R4 R7 ,.. I + R6 N R5 R6 0 R6 R4 15 0 R5 R5 A B C where R 4 , R 5 , R 6 and R 7 are the same or different, and signify hydrogen, lower alkyl, lower thioalkyl, lower alkoxy, aryloxy or thioaryl group, lower alkanoyl or aroyl group, 20 optionally substituted aryl group, amino, lower alkylamino, lower dialkylamino cycloalkylamino or heterocycloalkylamino group, lower alkylsulphonyl or arylsulphonyl WO 2008/094053 PCT/PT2007/000043 -28 group, halogen, haloalkyl, trifluoromethyl, cyano, nitro or heteroaryl group, or taken together signify aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings; the term alkyl means carbon chains, straight or branched, containing from one to six carbon atoms; the term aryl means a phenyl or naphthyl group, optionally substituted by alkoxy or 5 halogen groups; the term heterocycloalkyl represents a four to eight-membered cyclic ring optionally incorporating other atoms of oxygen, sulphur or nitrogen; the term heteroaryl represents a five or six-membered ring incorporating an atom of sulphur, oxygen or nitrogen; the term halogen represents fluorine, chlorine bromine or iodine; or a pharmacologically acceptable salt thereof, for the preparation of a medicament for the 10 prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day.
    [2] 2. Use of a compound of formula I 15 NO 2 Ri0 0 R20 0 RO N (X)n (Y)m R3 where R 1 and R 2 are the same or different and signify hydrogens or groups hydrolysable 20 under physiological conditions, optionally substituted lower alkanoyl or aroyl; X signifies a methylene group; Y represents an atom of oxygen, nitrogen or sulphur; n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1; R 3 signifies a pyridine N-oxide group according to the formula A, B, or C, which is connected as indicated by the unmarked bond: WO 2008/094053 PCT/PT2007/000043 -29 R7 R4 R7 R4 R7 'N. R6 N R5 R6 N0 R6 R4 I 0 R5 R5 A B C 5 where R4, R 5 , R 6 and R 7 are the same or different, and signify hydrogen, lower alkyl, lower thioalkyl, lower alkoxy, aryloxy or thioaryl group, lower alkanoyl or aroyl group, optionally substituted aryl group, amino, lower alkylamino, lower dialkylamino cycloalkylamino or heterocycloalkylamino group, lower alkylsulphonyl or arylsulphonyl group, halogen, haloalkyl, trifluoromethyl, cyano, nitro or heteroaryl group, or taken 10 together signify aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings; the term alkyl means carbon chains, straight or branched, containing from one to six carbon atoms; the term aryl means a phenyl or naphthyl group, optionally substituted by alkoxy or halogen groups; the term heterocycloalkyl represents a four to eight-membered cyclic ring optionally incorporating other atoms of oxygen, sulphur or nitrogen; the term heteroaryl 15 represents a five or six-membered ring incorporating an atom of sulphur, oxygen or nitrogen; the term halogen represents fluorine, chlorine bromine or iodine; or a pharmacologically acceptable salt thereof, for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said compound is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day 20 to about once every other day.
    [3] 3. Use according to claim 1 or claim 2, wherein the dosing regimen is once daily.
    [4] 4. Use according to claim 1 or claim 2, wherein the dosing regimen is twice daily 25
    [5] 5. Use according to claim 1 or claim 2, wherein the dosing regimen is once every other day. WO 2008/094053 PCT/PT2007/000043 -30
    [6] 6. Use according to any one of claims 1 to 5, wherein the central and peripheral nervous system associated disorder is treatable by a L-DOPA and/or AADC therapy.
    [7] 7. Use according to any one of claims 1 to 6, wherein the central and peripheral 5 nervous system associated disorder is a movement disorder or a schizoaffective disorder.
    [8] 8. Use according to claim 7 wherein the movement disorder is Parkinson's Disease.
    [9] 9. Use according to any one of claims 1 to 8, wherein the compound of formula I is 5 10 [3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene 1,2-diol.
    [10] 10. Package comprising a pharmaceutical composition comprising a compound of formula I 15 NO 2 R,0 R20 0 2 I N (X)n (Y)m R3 where R 1 and R 2 are the same or different and signify hydrogens or groups hydrolysable 20 under physiological conditions, optionally substituted lower alkanoyl or aroyl; X signifies a methylene group; Y represents an atom of oxygen, nitrogen or sulphur; n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1; R 3 signifies a pyridine N-oxide group according to the formula A, B, or C, which is connected as indicated by the unmarked bond: WO 2008/094053 PCT/PT2007/000043 -31 R7 R4 R7 R4 R7 , N.. R6 N R5 R6 N, 0 R6 R4 I 0 R5 R5 A B C 5 where R 4 , R 5 , 1 6 and R 7 are the same or different, and signify hydrogen, lower alkyl, lower thioalkyl, lower alkoxy, aryloxy or thioaryl group, lower alkanoyl or aroyl group, optionally substituted aryl group, amino, lower alkylamino, lower dialkylamino cycloalkylamino or heterocycloalkylamino group, lower alkylsulphonyl or arylsulphonyl group, halogen, haloalkyl, trifluoromethyl, cyano, nitro or heteroaryl group, or taken 10 together signify aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings; the term alkyl means carbon chains, straight or branched, containing from one to six carbon atoms; the term aryl means a phenyl or naphthyl group, optionally substituted by alkoxy or halogen groups; the term heterocycloalkyl represents a four to eight-membered cyclic ring optionally incorporating other atoms of oxygen, sulphur or nitrogen; the term heteroaryl 15 represents a five or six-membered ring incorporating an atom of sulphur, oxygen or nitrogen; the term halogen represents fluorine, chlorine bromine or iodine or a pharmacologically acceptable salt thereof, in combination with instructions to administer said composition with a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. 20
    [11] 11. Package according to claim 10, wherein the dosing regimen is once daily.
    [12] 12. Package according to claim 10, wherein the dosing regimen is twice daily 25
    [13] 13. Package according to claim 10, wherein the dosing regimen is once every other day. WO 2008/094053 PCT/PT2007/000043 - 32
    [14] 14. Package according to any one of claims 10 to 13, wherein the composition is for treatment of a central and peripheral nervous system associated disorder which is treatable by a L-DOPA and/or AADC therapy. 5
    [15] 15. Package according to any one of claims 10 to 14, wherein the composition is for treatment of a central and peripheral nervous system associated disorder which is a movement disorder or schizoaffective disorder.
    [16] 16. Package according to claim 15 wherein the movement disorder is Parkinson's 10 disease.
    [17] 17. Package according to any one of claims 10 to 16, wherein the compound of formula I is 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3 nitrobenzene-1,2-diol. 15
    [18] 18. Package according to any one of claims 10 to 17 wherein the package further comprises L-DOPA and/or an AADC and the instructions further include instructions on administration of the L-DOPA and/or AADC. 20
    [19] 19. Method of treating at least one condition or disease in a patient in need thereof comprising administering to the patient about twice every day to about once every other day a pharmacologically effective dose of a compound of formula I NO 2 R,0 R2 0 2 | N N / (X)n (Y)m R3 WO 2008/094053 PCT/PT2007/000043 - 33 where Ri and R 2 are the same or different and signify hydrogens or groups hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl; X signifies a methylene group; Y represents an atom of oxygen, nitrogen or sulphur; n represents the 5 number 0, 1, 2 or 3 and m represents the number 0 or 1; R 3 signifies a pyridine N-oxide group according to the formula A, B, or C, which is connected as indicated by the unmarked bond: R7 R4 R7 R4 R7 +N0 ++ R6 N R5 R6 0 R6 R4 0 R5 R5 10 A B C where R 4 , R 5 , R 6 and R 7 are the same or different, and signify hydrogen, lower alkyl, lower thioalkyl, lower alkoxy, aryloxy or thioaryl group, lower alkanoyl or aroyl group, optionally substituted aryl group, amino, lower alkylamino, lower dialkylamino 15 cycloalkylamino or heterocycloalkylamino group, lower alkylsulphonyl or arylsulphonyl group, halogen, haloalkyl, trifluoromethyl, cyano, nitro or heteroaryl group, or taken together signify aliphatic or heteroaliphatic rings or aromatic or heteroaromatic rings; the term alkyl means carbon chains, straight or branched, containing from one to six carbon atoms; the term aryl means a phenyl or naphthyl group, optionally substituted by alkoxy or 20 halogen groups; the term heterocycloalkyl represents a four to eight-membered cyclic ring optionally incorporating other atoms of oxygen, sulphur or nitrogen; the term heteroaryl represents a five or six-membered ring incorporating an atom of sulphur, oxygen or nitrogen; the term halogen represents fluorine, chlorine bromine or iodine or a pharmacologically acceptable salt thereof. 25
    [20] 20. Method as claimed in claim 19 wherein the administration is once daily.
    [21] 21. Method as claimed in claim 19 wherein the administration is twice daily. WO 2008/094053 PCT/PT2007/000043 - 34
    [22] 22. Method as claimed in claim 19 wherein the administration is once every other day.
    [23] 23. Method according to any one of claims 19 to 22, wherein the condition or disease is treatable by L-DOPA and/or AADC therapy. 5
    [24] 24. Method according to any one of claims 19 to 23, wherein the condition or disease is a central and peripheral nervous system associated disorder.
    [25] 25. Method according to any one of claims 19 to 24 wherein the condition or disease is 10 a movement or schizoaffective disorder.
    [26] 26. Method as claimed in claim 25 where in the movement disorder is Parkinson's disease. 15
    [27] 27. Method according to any one of claims 19 to 26, wherein the compound of fonnula I is 5- [3-(2,5-dichloro-4,6-dimethyl- 1 -oxy-pyridin-3-yl)-[ 1,2,4]oxadiazol-5-yl] -3 -nitro benzene-1,2-diol.
    [28] 28. Method according to any one of claims 19 to 27 wherein the method further 20 comprises the step of administering L-DOPA to the patient.
    [29] 29. Method according to any one of claims 19 to 28 wherein the method further comprises the step of administering an AADC to the patient.
    类似技术:
    公开号 | 公开日 | 专利标题
    US9745290B2|2017-08-29|Dosage regimen for COMT inhibitors
    US9446012B2|2016-09-20|Pharmaceutical compounds
    AU2009277196B2|2015-06-18|Administration regime for nitrocatechols
    BRPI0721213B1|2021-11-09|USE OF REPLACED NITROCATECOLS, AND PACKAGING
    Davis et al.2013|R20 IN
    同族专利:
    公开号 | 公开日
    PT2124947T|2017-10-25|
    CN101631548B|2014-08-27|
    KR20090104859A|2009-10-06|
    CN101631548A|2010-01-20|
    EP2124947B1|2017-07-19|
    US9745290B2|2017-08-29|
    EP2481410B1|2016-07-13|
    AU2007346018A2|2011-04-21|
    IL200020D0|2010-04-15|
    SI2481410T1|2017-01-31|
    CY1118311T1|2017-06-28|
    RU2518483C2|2014-06-10|
    JP5517629B2|2014-06-11|
    JP2011500506A|2011-01-06|
    NO20092905L|2009-10-29|
    ES2597705T3|2017-01-20|
    BRPI0721213A2|2014-03-18|
    DK2124947T3|2017-11-06|
    PT2481410T|2016-10-18|
    IL200020A|2016-07-31|
    RU2009132188A|2011-03-10|
    KR101522157B1|2015-05-28|
    CA2678391A1|2008-08-07|
    US20160009699A1|2016-01-14|
    ES2644049T3|2017-11-27|
    US20130331416A1|2013-12-12|
    ZA200905940B|2010-05-26|
    LT2481410T|2016-11-10|
    MX2009008051A|2009-08-12|
    AR065098A1|2009-05-13|
    HUE031317T2|2017-07-28|
    US20100113529A1|2010-05-06|
    DK2481410T3|2016-10-24|
    EP2481410A1|2012-08-01|
    AR109590A2|2018-12-26|
    CA2678391C|2017-01-17|
    PL2481410T3|2017-03-31|
    HRP20161261T8|2016-12-30|
    US8524746B2|2013-09-03|
    EP2124947A1|2009-12-02|
    HRP20161261T1|2016-12-02|
    WO2008094053A1|2008-08-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US660753A|1899-11-27|1900-10-30|Ferdinand-Christoph Von Heydebrand Und Der Lasa|Artificial fuel.|
    US1532178A|1921-07-25|1925-04-07|Louis A Godbold|Lubricator|
    FR1260080A|1960-03-22|1961-05-05|Materiel De Forage Soc De Fab|Sealed roller drill bit|
    US3647809A|1968-04-26|1972-03-07|Chinoin Gyogyszer Es Vegyeszet|Certain pyridyl-1 2 4-oxadiazole derivatives|
    US4022901A|1975-03-05|1977-05-10|E. R. Squibb & Sons, Inc.|3-Pyridinyl-5-isothiocyanophenyl oxadiazoles|
    US4264573A|1979-05-21|1981-04-28|Rowell Laboratories, Inc.|Pharmaceutical formulation for slow release via controlled surface erosion|
    US4386668A|1980-09-19|1983-06-07|Hughes Tool Company|Sealed lubricated and air cooled rock bit bearing|
    US5236952A|1986-03-11|1993-08-17|Hoffmann-La Roche Inc.|Catechol derivatives|
    DK175069B1|1986-03-11|2004-05-24|Hoffmann La Roche|Pyrocatechol derivatives|
    YU213587A|1986-11-28|1989-06-30|Orion Yhtymae Oy|Process for obtaining new pharmacologic active cateholic derivatives|
    DE3840954A1|1988-12-05|1990-06-07|Shell Int Research|PREPARATION OF 2-CHLORNICOTINIC ACID ESTERS|
    US5206372A|1990-06-05|1993-04-27|Shell Research Limited|Preparation of 2-chloropyridine derivatives|
    ES2066092T3|1990-11-29|1995-03-01|Wei Ming Pharmaceutical Mfg Co|COADJUVANTE FOR THE DIRECT TRAINING OF TABLETS.|
    US5622976A|1991-12-31|1997-04-22|Fujisawa Pharmaceutical Co., Ltd.|Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity|
    GB9419274D0|1994-09-23|1994-11-09|Orion Yhtymae Oy|New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde|
    DE19628617A1|1996-07-16|1998-01-22|Basf Ag|Direct tabletting aid|
    US6206110B1|1996-09-09|2001-03-27|Smith International, Inc.|Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit|
    EP1114039A1|1998-09-18|2001-07-11|Vertex Pharmaceuticals Incorporated|INHIBITORS OF p38|
    GB2344819A|1998-12-18|2000-06-21|Portela & Ca Sa|2-Phenyl-1--1-ethanones|
    FI109453B|1999-06-30|2002-08-15|Orion Yhtymae Oyj|Pharmaceutical composition|
    US6660753B2|1999-08-19|2003-12-09|Nps Pharmaceuticals, Inc.|Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists|
    CZ2002599A3|1999-08-19|2002-06-12|Nps Pharmaceuticals Inc.|Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists|
    FI20000635A0|2000-03-17|2000-03-17|Orion Yhtymae Oyj|Use of COMT inhibitors as an analgesic|
    SE0001438D0|2000-04-18|2000-04-18|Axon Chemicals Bv|New chemical compounds and their use in therapy|
    DE10029201A1|2000-06-19|2001-12-20|Basf Ag|Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature|
    GB2363792A|2000-06-21|2002-01-09|Portela & Ca Sa|Nitrocatechols|
    JP3965361B2|2000-08-24|2007-08-29|佐川急便株式会社|Card settlement method and system for service charges related to logistics or transportation|
    CN1166626C|2000-08-30|2004-09-15|李凌松|Position 3 or 4 substituted phenyl compound, its preparing process and its application|
    DE60140213D1|2000-11-28|2009-11-26|Zymogenetics L L C|CYTOKINE RECEPTOR ZCYTOR19|
    US20040097555A1|2000-12-26|2004-05-20|Shinegori Ohkawa|Concomitant drugs|
    WO2002051442A1|2000-12-26|2002-07-04|Takeda Chemical Industries, Ltd.|Concomitant drugs|
    DK1379525T3|2001-02-21|2007-12-27|Astrazeneca Ab|Heteropolycyclic Compounds and Their Use as Metabotropic Glutamate Receptor Antagonists|
    JP2004534779A|2001-05-30|2004-11-18|エルジーライフサイエンスリミテッド|Protein kinase inhibitors for disease treatment|
    MXPA03011196A|2001-06-08|2004-10-28|Cytovia Inc|Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs.|
    AU2002355170B2|2001-07-26|2007-06-07|Merck Patent Gmbh|Novel use of 2-[5--3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts|
    JP4379853B2|2001-10-05|2009-12-09|惠民製藥股▲分▼有限公司|Direct tableting formulations and methods of formulating adjuvants|
    JP2006516250A|2002-12-18|2006-06-29|サイトビアインコーポレイティッド|3,5-disubstituted- [1,2,4] -oxadiazoles and their derivatives and their use as caspase activators and apoptosis inducers|
    WO2005006945A2|2003-07-03|2005-01-27|The Salk Institute For Biological Studies|Methods for treating neural disorders and compounds useful therefor|
    CA2534921C|2003-08-06|2011-06-14|Vertex Pharmaceuticals Incorporated|Aminotriazole compounds useful as inhibitors of protein kinases|
    DE10338174A1|2003-08-20|2005-03-24|Lts Lohmann Therapie-Systeme Ag|Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease|
    US7300406B2|2003-09-30|2007-11-27|Carter Vandette B|Medical examination apparatus|
    GB0325956D0|2003-11-06|2003-12-10|Addex Pharmaceuticals Sa|Novel compounds|
    WO2005105780A2|2004-04-28|2005-11-10|Vertex Pharmaceuticals Incorporated|Compositions useful as inhibitors of rock and other protein kinases|
    JP2008519811A|2004-11-10|2008-06-12|オリオンコーポレーション|Treatment of restless leg syndrome|
    WO2006061697A1|2004-12-06|2006-06-15|Themis Laboratories Private Limited|Sulfonylurea compositions and a process for its preparation|
    US20080051441A1|2004-12-28|2008-02-28|Astrazeneca Ab|Aryl Sulphonamide Modulators|
    WO2006071184A1|2004-12-28|2006-07-06|Astrazeneca Ab|Aryl sulphonamide modulators|
    WO2006114400A1|2005-04-26|2006-11-02|Neurosearch A/S|Novel oxadiazole derivatives and their medical use|
    US20060257473A1|2005-05-11|2006-11-16|Porranee Puranajoti|Extended release tablet|
    GB0510139D0|2005-05-18|2005-06-22|Addex Pharmaceuticals Sa|Novel compounds B1|
    GB0510143D0|2005-05-18|2005-06-22|Addex Pharmaceuticals Sa|Novel compounds A1|
    JP4981794B2|2005-06-03|2012-07-25|アボット・ラボラトリーズ|Cyclobutylamine derivative|
    JP2007024970A|2005-07-12|2007-02-01|Miyakawa:Kk|Resin lens manufacturing method for increasing aperture efficiency of liquid crystal display and its manufacturing apparatus|
    US20090000437A1|2005-07-14|2009-01-01|Provo Craft And Novelty, Inc.|Methods for Cutting|
    GB0515327D0|2005-07-26|2005-08-31|Portela & Ca Sa|Comt inhibitors|
    PL1907382T3|2005-07-26|2016-01-29|Bial Portela & Ca Sa|Nitrocatechol derivatives as comt inhibitors|
    FR2889525A1|2005-08-04|2007-02-09|Palumed Sa|NOVEL POLYQUINOLINE DERIVATIVES AND THEIR THERAPEUTIC USE.|
    US20070048384A1|2005-08-26|2007-03-01|Joerg Rosenberg|Pharmaceutical compositions|
    US20090111778A1|2005-11-18|2009-04-30|Richard Apodaca|2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase|
    EP1956013B1|2005-11-30|2016-04-13|Fujifilm RI Pharma Co., Ltd.|Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition|
    GB0606774D0|2006-04-03|2006-05-10|Novartis Ag|Organic compounds|
    EP1845097A1|2006-04-10|2007-10-17|Portela &amp; Ca., S.A.|Oxadiazole derivatives as COMT inhibitors|
    PE20080906A1|2006-08-17|2008-07-05|Kemia Inc|HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS|
    US8486979B2|2006-12-12|2013-07-16|Abbvie Inc.|1,2,4 oxadiazole compounds and methods of use thereof|
    US20080167286A1|2006-12-12|2008-07-10|Abbott Laboratories|Pharmaceutical compositions and their methods of use|
    EP2481410B1|2007-01-31|2016-07-13|BIAL - Portela & Ca., S.A.|Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime|
    EP3311813B1|2007-08-27|2019-08-07|Dart Neuroscience Ltd|Therapeutic isoxazole compounds|
    WO2009108077A2|2008-02-28|2009-09-03|Bial - Portela & Ca., S.A.|Pharmaceutical composition for poorly soluble drugs|
    EP2276758B1|2008-03-17|2016-01-06|Bial-Portela & CA, S.A.|Crystal forms of 5- [3- [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol|
    BRPI0913913A2|2008-07-29|2015-10-13|Bial Portela & Ca Sa|dosing regimen for nitrocathecols|
    BRPI1014865B1|2009-04-01|2020-03-17|Bial - Portela & C.A., S.A.|Composition comprising granules comprising 2,5-dichloro-3- - 1,2,4-oxadiazol-3-yl) - 4,6-dimethylpyridine 1-oxide and pharmaceutical formulation|
    WO2010114405A2|2009-04-01|2010-10-07|Bial - Portela & Ca., S.A.|Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same|
    MX336187B|2010-03-04|2016-01-07|Orion Corp|Use of levodopa, carbidopa and entacapone for treating parkinson's disease.|
    US20140045900A1|2011-02-11|2014-02-13|Bial-Portela & Ca, S.A.|Administration regime for nitrocatechols|
    DK2791134T3|2011-12-13|2019-12-09|BIAL PORTELA & Cª S A|CHEMICAL COMPOUNDS USED AS INTERMEDIATE FOR THE PREPARATION OF A CATECHOL-O-METHYL TRANSPHERASE INHIBITORS|IL169855A|2005-07-25|2014-05-28|Elta Systems Ltd|System and method for enabling determination of a position of a receiver|
    PL1907382T3|2005-07-26|2016-01-29|Bial Portela & Ca Sa|Nitrocatechol derivatives as comt inhibitors|
    EP1845097A1|2006-04-10|2007-10-17|Portela &amp; Ca., S.A.|Oxadiazole derivatives as COMT inhibitors|
    US7834039B2|2006-12-15|2010-11-16|Abbott Laboratories|Oxadiazole compounds|
    EP2481410B1|2007-01-31|2016-07-13|BIAL - Portela & Ca., S.A.|Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime|
    WO2009108077A2|2008-02-28|2009-09-03|Bial - Portela & Ca., S.A.|Pharmaceutical composition for poorly soluble drugs|
    EP2276758B1|2008-03-17|2016-01-06|Bial-Portela & CA, S.A.|Crystal forms of 5- [3-[1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol|
    BRPI0913913A2|2008-07-29|2015-10-13|Bial Portela & Ca Sa|dosing regimen for nitrocathecols|
    WO2010114405A2|2009-04-01|2010-10-07|Bial - Portela & Ca., S.A.|Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same|
    BRPI1014865B1|2009-04-01|2020-03-17|Bial - Portela & C.A., S.A.|Composition comprising granules comprising 2,5-dichloro-3-- 1,2,4-oxadiazol-3-yl) - 4,6-dimethylpyridine 1-oxide and pharmaceutical formulation|
    KR20120092175A|2009-12-04|2012-08-20|죤 이. 그랜트|Treating impulse control disorders with catechol-o- methyl-transferase inhibitors|
    US20140045900A1|2011-02-11|2014-02-13|Bial-Portela & Ca, S.A.|Administration regime for nitrocatechols|
    DK2791134T3|2011-12-13|2019-12-09|BIAL PORTELA & Cª S A|CHEMICAL COMPOUNDS USED AS INTERMEDIATE FOR THE PREPARATION OF A CATECHOL-O-METHYL TRANSPHERASE INHIBITORS|
    WO2016083863A1|2014-11-28|2016-06-02|Bial - Portela & Ca, S.A.|Medicaments for slowing parkinson's disease|
    WO2016123577A1|2015-01-30|2016-08-04|Lieber Institute For Brain Development|Comt inhibiting methods and compositions|
    EP3250209A4|2015-01-30|2018-07-04|Lieber Institute For Brain Development|Comt inhibiting methods and compositions|
    CA3006189A1|2015-11-25|2017-06-01|Lieber Institute For Brain Development|Comt inhibiting methods and compositions|
    US20210338651A1|2018-10-05|2021-11-04|Neurocrine Biosciences, Inc.|Methods for the administration of comt inhibitors|
    WO2020072884A1|2018-10-05|2020-04-09|Neurocrine Biosciences, Inc.|Methods for the administration of comt inhibitors|
    USD912395S1|2019-11-01|2021-03-09|Jondarius Brown|Apparatus for storing earphones|
    法律状态:
    2011-04-21| DA3| Amendments made section 104|Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 MAR 2011 |
    2012-02-02| MK1| Application lapsed section 142(2)(a) - no request for examination in relevant period|
    优先权:
    申请号 | 申请日 | 专利标题
    EP07002091.2||2007-01-31||
    EP07002091||2007-01-31||
    PCT/PT2007/000043|WO2008094053A1|2007-01-31|2007-10-10|Dosage regimen for comt inhibitors|
    [返回顶部]